다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

ADAG

Adagene (ADAG)

Adagene Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ADAG

1 2 3 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/23	05:45	GlobeNewswire Inc.	Adagene to Present at Investor Conferences in June	NASDAQ:ADAG	Adagene Inc
2024/03/29	22:00	GlobeNewswire Inc.	Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
2024/03/08	06:01	GlobeNewswire Inc.	Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board	NASDAQ:ADAG	Adagene Inc
2024/03/02	06:30	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:ADAG	Adagene Inc
2024/02/27	22:00	GlobeNewswire Inc.	Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	NASDAQ:ADAG	Adagene Inc
2024/02/09	20:08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2024/02/09	20:00	GlobeNewswire Inc.	Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stab	NASDAQ:ADAG	Adagene Inc
2024/01/17	07:01	GlobeNewswire Inc.	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	NASDAQ:ADAG	Adagene Inc
2024/01/17	07:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2024/01/04	19:00	GlobeNewswire Inc.	Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium	NASDAQ:ADAG	Adagene Inc
2023/11/04	01:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/11/04	01:00	GlobeNewswire Inc.	Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023	NASDAQ:ADAG	Adagene Inc
2023/10/12	21:00	GlobeNewswire Inc.	Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	NASDAQ:ADAG	Adagene Inc
2023/09/29	19:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/09/07	19:00	GlobeNewswire Inc.	Adagene to Present at Investor and Scientific Conferences in September	NASDAQ:ADAG	Adagene Inc
2023/08/31	20:32	GlobeNewswire Inc.	Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
2023/08/31	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/07/08	05:34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/05/04	22:01	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
2023/05/04	22:00	GlobeNewswire Inc.	Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate	NASDAQ:ADAG	Adagene Inc
2023/04/28	20:06	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
2023/04/28	20:03	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	NASDAQ:ADAG	Adagene Inc
2023/04/28	20:00	GlobeNewswire Inc.	Adagene Announces Updates to its Board of Directors	NASDAQ:ADAG	Adagene Inc
2023/04/18	22:27	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
2023/04/18	22:17	GlobeNewswire Inc.	Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors	NASDAQ:ADAG	Adagene Inc
2023/03/29	06:07	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
2023/03/29	05:30	GlobeNewswire Inc.	Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
2023/03/15	07:00	GlobeNewswire Inc.	Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April	NASDAQ:ADAG	Adagene Inc
2023/03/06	09:39	GlobeNewswire Inc.	Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board	NASDAQ:ADAG	Adagene Inc
2023/02/09	22:16	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:ADAG	Adagene Inc

검색 관련기사 보기:NASDAQ:ADAG

1 2 3 다음 >>

Ons Acquisition

Vontobel Financial Produ...

FTSEurofirst 300 Eurozon...

USCF Energy Commodity St...

세이브존I&C

Saint Jean Groupe

Simplify Exchang

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관